isabelobrien, Author at European Medical Journal - Page 3 of 29

Novo Nordisk announces significant leadership reshuffle

Novo Nordisk has announced major leadership changes, with EVP Camilla Sylvest departing and Ludovic Helfgott taking on an expanded role.

The word spotlight on a blue background

Spotlight: March 2025

From the latest news impacting the UK’s NHS to large industry acquisitions, March brought a range of impactful news.

Spoonful of technology: Jan-March 2025

Discover the latest pharma innovations, from needle-free vaccines to NHS data access and interactive case studies in medical education.

Illustration of a heart with a monitor

Could gene therapy transform heart failure treatment?

A gene therapy for heart failure with preserved ejection fraction (HFpEF) has shown promising early results.

Sanofi's chlamydia vaccine fast-tracked by FDA

This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.

Pharma’s trillion-dollar opportunity: Investing in women’s health

Women’s health remains chronically underfunded, yet closing the gap could unlock huge value for women and the global economy.

Pharma’s innovation ROI: Gains made, challenges ahead

The biopharmaceutical industry’s return on investment in innovation is increasing, but R&D costs are rising, according to a new Deloitte report.

British government buildings

VPAG hikes put UK life sciences at risk, warns pharma

The industry already contributes more than £17.6 billion directly to the UK economy, but it believes that growth has stagnated because of VPAG.

Pfizer completes exit from Haleon

Pfizer has announced plans to sell its remaining stake in Haleon plc, divesting approximately 662 million shares.

5 minutes with... Prof Alexander Egeberg, LEO Pharma

Prof Alexander Egeberg, Vice President, Head of Global Medical Affairs, LEO Pharma, reveals how the company is tackling unmet needs in dermatology.